Only 21.7% of more than 318 000 women initiated systemic hormone therapy (HT) within 12 months of a natural menopause diagnosis, and fewer than 40% of those who started treatment remained on their initial treatment episode at 1 year, according to late-breaking research presented at The Menopause Society 2026 Annual Meeting in San Diego.
The retrospective study , presented by Intira Sriprasert, MD, PhD, of the University of Southern California, analyzed MarketScan Research Databases from 2009 to 2022 to examine patterns of systemic HT initiation and treatment duration among women aged 45 to 60 years.
Of the 318 621 eligible women, 69 203 (21.7%) initiated systemic HT within 12 months of menopause diagnosis, while 249,418 (78.3%) did not.
The most common initial treatment was estrogen plus progestogen (52.5%), followed by estrogen alone (32.4%) and progestogen alone (15.1%).
Only 21.7% of more than 318 000 women initiated systemic hormone therapy (HT) within 12 months of a natural menopause diagnosis, and fewer than 40% of those who started treatment remained on their initial treatment episode at 1 year, according to late-breaking research presented at The Menopause Society 2026 Annual Meeting in San Diego.
The retrospective study , presented by Intira Sriprasert, MD, PhD, of the University of Southern California, analyzed MarketScan Research Databases from 2009 to 2022 to examine patterns of systemic HT initiation and treatment duration among women aged 45 to 60 years.
Of the 318 621 eligible women, 69 203 (21.7%) initiated systemic HT within 12 months of menopause diagnosis, while 249,418 (78.3%) did not. The most common initial treatment was estrogen plus progestogen (52.5%), followed by estrogen alone (32.4%) and progestogen alone (15.1%).
